Table 3 Selected ongoing clinical application of peptide-based cancer vaccines (2016–2021)
From: Cancer vaccines as promising immuno-therapeutics: platforms and current progress
NCT number | Status | Targeted antigens/biological | Conditions | Phases | Category |
|---|---|---|---|---|---|
NCT04747002 | Recruiting | DSP-7888 | Acute Myeloid Leukemia in Remission | II | Peptide |
NCT03946358 | Recruiting | UCPVax | Squamous Cell Carcinoma of the Head and Neck, Anal Canal Cancer, Cervical Cancer | II | Peptide |
NCT04263051 | Recruiting | UCPVax | Advanced Non-small Cell Lung Cancer | II | Peptide |
NCT04382664 | Recruiting | UV1 | Malignant Melanoma | II | Peptide |
NCT04114825 | Active, not recruiting | RV001V | Prostate Cancer Recurrent | II | Peptide |
NCT02938442 | Recruiting | P10s-PADR | Triple Negative Breast Cancer, Breast Neoplasms | I/II | Peptide |
NCT04280848 | Recruiting | Telomerase | Glioblastoma | I/II | Peptide |
NCT02818426 | Recruiting | UCPVax | Metastatic Non-small Cell Lung Cancer | I/II | Peptide |
NCT04369937 | Recruiting | HPV-16 E6/E7 | HPV-Related Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma | II | Peptide |
NCT02654587 | Active, not recruiting | OSE2101 | Non-Small Cell Lung Cancer | III | Peptide |
NCT03149003 | Recruiting | DSP-7888 | Glioblastoma | III | Peptide |
NCT04024800 | Active, not recruiting | AE37 Peptide | Triple-negative Breast Cancer | II | Peptide |
NCT02865135 | Active, not recruiting | DPX-E7 | Cancer of Head and Neck, Cancer of Cervix, Cancer of Anus | I/II | Peptide |
NCT03311334 | Recruiting | DSP-7888 | Renal Cell Carcinoma, Urothelial Carcinoma, Primary Peritoneal Cancer, Ovarian Cancer, | I/II | Peptide |
NCT03012100 | Recruiting | Folate Receptor-α | Breast Cancer | II | Peptide |
NCT03606967 | Recruiting | Neoantigens | Breast Carcinoma | II | Peptide |
NCT04580771 | Recruiting | HPV-16 E6/E7 | Cervical Cancer | II | Peptide |
NCT04206254 | Not yet recruiting | gp96 | Liver Cancer | II/III | Peptide |
NCT03029403 | Recruiting | DPX-Survivac | Advanced Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer | II | Peptide |
NCT02636582 | Active, not recruiting | NeuVax | Breast Ductal Carcinoma in Situ | II | Peptide |
NCT03715985 | Recruiting | Neoantigens | Malignant Melanoma, Non-Small Cell Lung Cancer Metastatic, Bladder Urothelial Carcinoma, Metastatic | I/II | Peptide |
NCT04197687 | Recruiting | Multi-epitope HER2 Peptide | Breast Cancer | II | Peptide |
NCT03560752 | Recruiting | CMV-MVA Triplex | CMV Viremia in Participants with Blood Cancer Undergoing Donor Stem Cell Transplant | II | Peptide |
NCT04300244 | Recruiting | UV1Â vaccine | Malignant Mesothelioma | II | Peptide |
NCT04106115 | Not yet recruiting | S-488210/S-488211 | Bladder Cancer | I/II | Peptide |
NCT03559413 | Active, not recruiting | Neoantigens | Primary, Relapsed Acute Lymphoblastic Leukemia of Childhood, Adolescents and Young Adults | I/II | Peptide |
NCT03258008 | Active, not recruiting | ISA101b | Oropharyngeal Cancer | II | Peptide |
NCT04051307 | Recruiting | Arginase1, PD-L1 | Polycythemia Vera, Essential Thrombocythemia | I/II | Peptide |
NCT04646005 | Recruiting | ISA101b | Cervical Cancer | II | Peptide |
NCT03821272 | Recruiting | PepCan | Head and Neck Cancer | I/II | Peptide |
NCT03761914 | Recruiting | WT1 | Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer | I/II | Peptide |
NCT04116658 | Recruiting | EO2401 | Glioblastoma | I/II | Peptide |
NCT02960230 | Recruiting | H3.3K27M Peptide | Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | I/II | Peptide |
NCT03018288 | Active, not recruiting | HSPPC-96 | Glioblastoma | II | Peptide |
NCT02795988 | Active, not recruiting | IMU-131 | Gastrointestinal Neoplasms, Adenocarcinoma | I/II | Peptide |
NCT02785250 | Active, not recruiting | DPX-Survivac | Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Peritoneal Cancer | I/II | Peptide |
NCT04060277 | Recruiting | Triplex | Leukemia, Lymphoma | II | Peptide |
NCT03848039 | Not yet recruiting | Gardasil-9 | Cervical Intraepithelial Neoplasia | III | Protein |
NCT03979014 | Not yet recruiting | GARDASIL9 | Neoplasia | III | Protein |
NCT02955290 | Active, not recruiting | CIMAvax | Non-small Cell Lung Cancer, Squamous Head and Neck Cancer | I/II | Protein |
NCT04910802 | Recruiting | Gardasil9 | HPV Infection, CIN 2, 3, Cervical Cancer | IV | Protein |
NCT03284866 | Recruiting | Gardasil 9 | AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia, HIV Infection | III | Protein |
NCT03206047 | Active, not recruiting | CDX-1401 | Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal | I/II | Protein |
NCT03728881 | Active, not recruiting | Cervarix, Gardasil | Human Papillomavirus-Related Cervical Carcinoma | III | Protein |
NCT02568566 | Active, not recruiting | Gardasil 9 | Human Papillomavirus-Related Carcinoma | II | Protein |
NCT03180034 | Active, not recruiting | Gardasil, DTaP, Cervarix | Human Papillomavirus-Related Cervical Carcinoma | IV | Protein |
NCT04635423 | Recruiting | V503 | Warts, Genital, Neoplasms, Anal | III | Protein |
NCT04782895 | Active, not recruiting | Gardasil®9 | Cervical Cancer, Condylomata Acuminata | III | Protein |
NCT02834637 | Active, not recruiting | Cervarix, Gardasil 9 | Human Papilloma Virus | III | Protein |
NCT04508309 | Recruiting | Gardasil®, Cecolin® | Cervical Cancer | III | Protein |
NCT03675256 | Active, not recruiting | Gardasil 9, Cervarix | Papillomavirus Infections | IV | Protein |
NCT03036930 | Active, not recruiting | Gardasil 9 | Human Papillomavirus Infection | II | Protein |
NCT04274153 | Recruiting | Gardasil9 | Immunization, Human Papilloma Virus | IV | Protein |
NCT03702231 | Active, not recruiting | Zoster Vaccine Recombinant | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | II | Protein |
NCT04459221 | Recruiting | Gardasil 9 | Papilloma Viral Infection | IV | Protein |
NCT03579654 | Not yet recruiting | PSA, IL-2, GM-CSF | Prostate Cancer | II | Protein |